Search results for "Phase 3 trial"

When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients

When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients

Crohn’s disease remains one of the most challenging inflammatory bowel diseases to manage. Patients with refractory—or treatment-resistant—Crohn’s...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological approach relied on aggressive...
Seoul National University Hospital to Lead 30 Billion Won Bidirectional Brain-to-Robot BCI Clinical Trials

Seoul National University Hospital to Lead 30 Billion Won Bidirectional Brain-to-Robot BCI Clinical Trials

The idea of walking by thought alone—and even regaining sensations in the soles of the feet—is edging closer to reality.
Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T)...
RNA Therapy Emerges as Critical Fast-Track for Cholesterol Control After Heart Attacks

RNA Therapy Emerges as Critical Fast-Track for Cholesterol Control After Heart Attacks

Myocardial infarction and unstable angina are life-threatening medical emergencies that occur when the blood vessels...
Celltrion Advances Next-Generation Immuno-Oncology Candidate with Strong Preclinical Results

Celltrion Advances Next-Generation Immuno-Oncology Candidate with Strong Preclinical Results

Celltrion has announced promising preclinical data for its investigational immuno-oncology candidate, CT-P72/ABP-102,...
FDA Grants Streamlined Path for MediPost’s Cartistem, Slashing U.S. Trial Burden

FDA Grants Streamlined Path for MediPost’s Cartistem, Slashing U.S. Trial Burden

The U.S. Food and Drug Administration has agreed to a significantly streamlined clinical path for Cartistem, a landmark...
Expanded Health Insurance Coverage Lowers Barrier to Care for Rare Heart and Kidney Disorder

Expanded Health Insurance Coverage Lowers Barrier to Care for Rare Heart and Kidney Disorder

Patients suffering from light-chain amyloidosis, a rare and debilitating blood disorder that causes abnormal proteins...
Will a 'Second Gleevec' Emerge? The Race Heats Up for Rare Gastrointestinal Cancer Breakthroughs

Will a 'Second Gleevec' Emerge? The Race Heats Up for Rare Gastrointestinal Cancer Breakthroughs

A rare cancer can form in the wall of the stomach or intestines: gastrointestinal stromal tumor, or GIST.
South Korean Biotechs Race to Conquer the Untapped Global MASH Market

South Korean Biotechs Race to Conquer the Untapped Global MASH Market

Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.